Health TrialsbyHealthPanel

Use of Novel Plasma and Urinary Biomarkers to Predict the Development of Hepatorenal Syndrome in Cirrhotic Patients

ConditionHepatorenal Syndrome
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-90
SponsorThe University of Hong Kong

About this trial

This study investigated the use of novel plasma and urinary biomarkers to predicte the development of hepatorenal syndrome in patients with advanced cirrhosis. The biomarkers investigated include plasma cystatin C, plasma NGAL, plasma NAG, plasma IL-18, plasma ADMA, plasma BTP, urinary KIM-1 and urinary LFABP. These biomarkers will be checked in advanced cirrhotic patients who have or have not developed hepatorenal syndrome and compared between the two groups. These biomarkers will also be correlated with the occurence of hepatorenal syndrome.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients with advanced cirrhosis (Child's B or C) referred for liver transplantation

Willing to give informed consent

Disqualifiers

Patients with co-existing renal diseases

Trial population

Patients with advanced cirrhosis (Child's B or C) referred for liver transplantation

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

100 Participants
are grouped into 2 trial groups
Group A: Hepatorenal syndrome group
Group B: Non-hepatorenal syndrome group

Trial outcomes

Primary outcomes

1

Hepatorenal syndrome

Time frame
12 weeks

Secondary outcomes

1

Mortality

Time frame
6 months
2

Chronic renal impairment

Time frame
6 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

The University of Hong Kong

Lead sponsor

The Hong Kong Society of Nephrology

Collaborator

Source ClinicalTrials.gov
Apply now